File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
  • Basic View
  • Metadata View
  • XML View
TitleErlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
 
AuthorsWong, MKY
Lo, AI
Lam, WK
Lam, B
Ip, MSM
Ho, JCM
 
Issue Date2009
 
PublisherLippincott Williams & Wilkins.
 
CitationThe 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263 [How to Cite?]
DOI: http://dx.doi.org/10.1097/JTO.0b013e3181b9c77e
 
AbstractBACKGROUND: Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. PURPOSE: To evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. METHOD: Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib. RESULTS: A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 11 (52.4%) patients with erlotinib. There was an association between the disease control with gefitinib and erlotinib (p=0.016). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. CONCLUSION: For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib.
 
ISSN1556-0864
2012 Impact Factor: 4.473
2012 SCImago Journal Rankings: 1.766
 
DOIhttp://dx.doi.org/10.1097/JTO.0b013e3181b9c77e
 
DC FieldValue
dc.contributor.authorWong, MKY
 
dc.contributor.authorLo, AI
 
dc.contributor.authorLam, WK
 
dc.contributor.authorLam, B
 
dc.contributor.authorIp, MSM
 
dc.contributor.authorHo, JCM
 
dc.date.accessioned2011-06-02T02:10:06Z
 
dc.date.available2011-06-02T02:10:06Z
 
dc.date.issued2009
 
dc.description.abstractBACKGROUND: Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. PURPOSE: To evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. METHOD: Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib. RESULTS: A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 11 (52.4%) patients with erlotinib. There was an association between the disease control with gefitinib and erlotinib (p=0.016). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. CONCLUSION: For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib.
 
dc.description.otherThe 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263
 
dc.identifier.citationThe 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263 [How to Cite?]
DOI: http://dx.doi.org/10.1097/JTO.0b013e3181b9c77e
 
dc.identifier.doihttp://dx.doi.org/10.1097/JTO.0b013e3181b9c77e
 
dc.identifier.epageS719
 
dc.identifier.hkuros172607
 
dc.identifier.issn1556-0864
2012 Impact Factor: 4.473
2012 SCImago Journal Rankings: 1.766
 
dc.identifier.issue9, suppl. 1
 
dc.identifier.openurl
 
dc.identifier.spageS719
 
dc.identifier.urihttp://hdl.handle.net/10722/133873
 
dc.identifier.volume4
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins.
 
dc.relation.ispartofJournal of Thoracic Oncology
 
dc.rightsThis is a non-final version of an article published in final form in (provide complete journal citation)
 
dc.titleErlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wong, MKY</contributor.author>
<contributor.author>Lo, AI</contributor.author>
<contributor.author>Lam, WK</contributor.author>
<contributor.author>Lam, B</contributor.author>
<contributor.author>Ip, MSM</contributor.author>
<contributor.author>Ho, JCM</contributor.author>
<date.accessioned>2011-06-02T02:10:06Z</date.accessioned>
<date.available>2011-06-02T02:10:06Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>The 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263</identifier.citation>
<identifier.issn>1556-0864</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/133873</identifier.uri>
<description.abstract>BACKGROUND: Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. PURPOSE: To evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. METHOD: Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib. RESULTS: A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 11 (52.4%) patients with erlotinib. There was an association between the disease control with gefitinib and erlotinib (p=0.016). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. CONCLUSION: For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins.</publisher>
<relation.ispartof>Journal of Thoracic Oncology</relation.ispartof>
<rights>This is a non-final version of an article published in final form in (provide complete journal citation)</rights>
<title>Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1556-0864&amp;volume=4&amp;issue=9, suppl. 1&amp;spage=S719, abstract no. P1.263&amp;epage=&amp;date=2009&amp;atitle=Erlotinib+as+salvage+treatment+after+failure+to+first-line+gefitinib+in+non-small+cell+lung+cancer</identifier.openurl>
<identifier.doi>10.1097/JTO.0b013e3181b9c77e</identifier.doi>
<identifier.hkuros>172607</identifier.hkuros>
<identifier.volume>4</identifier.volume>
<identifier.issue>9, suppl. 1</identifier.issue>
<identifier.spage>S719</identifier.spage>
<identifier.epage>S719</identifier.epage>
<description.other>The 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263</description.other>
</item>